‘FROM’ Season 4, Episode 2 Recap And Review: The Lake Of Tears

FROM Season 4, Episode 2 brings us full circle, as Julie begins to time travel and Ethan is reminded of the Lake of Tears.

Elon Musk Boosts New Yorker’s Sam Altman Exposé on X as Trial Begins

The move comes as the trial for Elon Musk’s lawsuit against OpenAI kicks off in federal court in Oakland.

Microsoft drops its exclusive licence to OpenAI’s technology
Microsoft drops its exclusive licence to OpenAI’s technology

Both companies announced the revised agreement in a joint statement on Monday. Microsoft retains a non-exclusive licence to OpenAI’s intellectual property through 2032, remains the primary cloud partner, and keeps its 27% equity stake. OpenAI will cont…

America Can’t Lower Healthcare Costs Without A Moonshot

Why fee-for-service and value-based care are failing, and why only a “moonshot” in healthcare payment models can make care affordable again.

Apple TV Lands Another 100% Rotten Tomatoes Scored Show

Apple TV has a tremendous batting average when it comes to original shows, and this week, we have a 100% Rotten Tomatoes scored one.

The Man Behind AlphaGo Thinks AI Is Taking the Wrong Path

David Silver has a new billion-dollar company that aims to build AI “superlearners.”

‘Euphoria’ Episode 3 Has Sydney Sweeney’s Best Cassie Performance Ever

I was very impressed with Sweeney’s performance as Cassie last night, the best in this series, and probably, honestly, one of her best across her movie roles as well.

Why A Hearing Industry Deal Matters To Every Business Leader

In a defining moment for GN Group and Amplifon, a look at the kind of leadership that prioritizes discipline, focus, and long-term value over visibility.

Finding Hidden Geothermal Power With AI

This week’s Current Climate newsletter also looks at how SpaceX’s IPO could leave Tesla eating rocket dust and the need for better forest management in a warming world

Trump’s Orders Elevate The Medical Status Of Psychedelics And Cannabis

Trump’s orders move the U.S. a few steps closer to more widespread research on and use of two sets of controversial yet promising drugs, psychedelic and cannabis products